CN114224907A - 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 - Google Patents

包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Download PDF

Info

Publication number
CN114224907A
CN114224907A CN202111383325.9A CN202111383325A CN114224907A CN 114224907 A CN114224907 A CN 114224907A CN 202111383325 A CN202111383325 A CN 202111383325A CN 114224907 A CN114224907 A CN 114224907A
Authority
CN
China
Prior art keywords
various embodiments
substituted
unsubstituted
cpg
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111383325.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·T·科尔蒂莱夫斯基
P·M·希维德尔斯基
D·F·莫雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN114224907A publication Critical patent/CN114224907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202111383325.9A 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Pending CN114224907A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562187878P 2015-07-02 2015-07-02
US62/187,878 2015-07-02
US201562264026P 2015-12-07 2015-12-07
US62/264,026 2015-12-07
PCT/US2016/040361 WO2017004357A1 (en) 2015-07-02 2016-06-30 Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
CN201680047408.1A CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680047408.1A Division CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN114224907A true CN114224907A (zh) 2022-03-25

Family

ID=57609287

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111383325.9A Pending CN114224907A (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
CN201680047408.1A Active CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680047408.1A Active CN107980001B (zh) 2015-07-02 2016-06-30 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Country Status (6)

Country Link
US (3) US10758624B2 (cg-RX-API-DMAC7.html)
EP (1) EP3316894A4 (cg-RX-API-DMAC7.html)
JP (2) JP7073109B2 (cg-RX-API-DMAC7.html)
CN (2) CN114224907A (cg-RX-API-DMAC7.html)
CA (1) CA2991052A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017004357A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908094A (zh) * 2022-05-31 2022-08-16 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206475B2 (en) * 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
CN108291228A (zh) 2015-04-22 2018-07-17 米纳治疗有限公司 C/EBPαSARNA组合物和使用方法
WO2017004357A1 (en) * 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
CN110248665A (zh) 2017-02-06 2019-09-17 Mpeg La有限责任公司 具有降低的肾清除的多聚体寡核苷酸
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11554178B2 (en) 2017-06-30 2023-01-17 City Of Hope Compositions and methods of modulating macrophage activity
WO2019048632A1 (en) * 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
EP3778893A4 (en) * 2018-04-10 2022-04-20 Ractigen Therapeutics P21 GENE EXPRESSION ACTIVATION METHOD
WO2019241766A1 (en) * 2018-06-15 2019-12-19 City Of Hope Oligonucleotide-based proteolysis targeting chimera
CN109762042B (zh) * 2018-09-21 2022-04-08 河北艾克美冀生物科技有限公司 一种治疗癌症的药物、其合成方法和应用
US20230287406A1 (en) * 2019-03-04 2023-09-14 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
AU2020322440A1 (en) * 2019-07-26 2022-02-24 Mina Therapeutics Limited Compositions and methods of using C/EBP alpha saRNA
WO2021108702A1 (en) 2019-11-26 2021-06-03 City Of Hope Microrna as a therapeutic agent
KR102433981B1 (ko) * 2020-12-15 2022-08-19 대구가톨릭대학교산학협력단 HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물
WO2022166849A1 (en) * 2021-02-08 2022-08-11 Ractigen Therapeutics Multi-valent oligonucleotide agent and methods of use thereof
WO2023034853A2 (en) * 2021-08-31 2023-03-09 City Of Hope Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
JP2025535719A (ja) * 2022-10-07 2025-10-28 シティ・オブ・ホープ 二本鎖オリゴヌクレオチド及び使用方法
CN120390802A (zh) * 2022-11-29 2025-07-29 隆萨销售股份有限公司 使用靶向stat6的细胞外囊泡-aso的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046259A1 (en) * 2004-05-27 2006-03-02 The Gov. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Differential expression of molecules associated with acute stroke
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
CN101848923A (zh) * 2007-05-01 2010-09-29 希望之城 通过双链rna特异性抑制基因表达的方法和组合物
US20140287987A1 (en) * 2007-01-26 2014-09-25 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
CN107980001A (zh) * 2015-07-02 2018-05-01 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20080214436A1 (en) * 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
US20110250138A1 (en) * 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
WO2012128785A1 (en) 2011-03-22 2012-09-27 City Of Hope Methods and compositions for the treatment of cancer or other diseases
KR20190092590A (ko) * 2011-04-01 2019-08-07 아이오니스 파마수티컬즈, 인코포레이티드 전사 신호 전달 인자 및 활성 인자 3(stat3) 발현 조절
WO2014047649A1 (en) * 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
EP3483273A1 (en) * 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
AU2014236370C1 (en) * 2013-03-14 2019-01-17 City Of Hope 5-bromo-indirubins
WO2015077657A2 (en) * 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046259A1 (en) * 2004-05-27 2006-03-02 The Gov. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Differential expression of molecules associated with acute stroke
US20100210707A1 (en) * 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
US20140287987A1 (en) * 2007-01-26 2014-09-25 City Of Hope Methods and compositions for the treatment of cancer or other diseases
CN101848923A (zh) * 2007-05-01 2010-09-29 希望之城 通过双链rna特异性抑制基因表达的方法和组合物
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
CN107980001A (zh) * 2015-07-02 2018-05-01 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908094A (zh) * 2022-05-31 2022-08-16 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Also Published As

Publication number Publication date
US11464865B2 (en) 2022-10-11
JP7073109B2 (ja) 2022-05-23
CA2991052A1 (en) 2017-01-05
JP2022116006A (ja) 2022-08-09
US10758624B2 (en) 2020-09-01
WO2017004357A1 (en) 2017-01-05
JP7459168B2 (ja) 2024-04-01
US20210038733A1 (en) 2021-02-11
EP3316894A4 (en) 2019-06-19
JP2018519831A (ja) 2018-07-26
CN107980001A (zh) 2018-05-01
US20180185497A1 (en) 2018-07-05
US12611462B2 (en) 2026-04-28
EP3316894A1 (en) 2018-05-09
US20220401563A1 (en) 2022-12-22
CN107980001B (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
CN107980001B (zh) 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
US12227745B2 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
EP3228326A1 (en) Nucleic acid linked to a trivalent glycoconjugate
JP2025041739A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
JP2022534069A (ja) 核酸、薬物組成物及び複合体並びに調製方法と使用
EP3974533A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP2024505035A (ja) 中枢神経系における遺伝子発現を阻害するための組成物および方法
KR20260046091A (ko) 프로그램된 사멸 리간드 수용체(pd-l1) 발현을 위한 조성물 및 방법
CN120303403A (zh) Stat3靶向寡核苷酸及其用途
CN107709561A (zh) 修饰的siRNA及含有该修饰的siRNA的药物组合物
HK40110850A (en) Nucleic acids, pharmaceutical compositions and conjugates, and preparation method and application thereof
HK40057145B (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
TW202417049A (zh) 寡核苷酸遞送劑、藥物組合物及其使用方法
HK40057142B (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
HK40056327A (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
HK40056327B (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
HK40051484B (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
HK40053351B (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220325